Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine in Endometrial Cancer
NCT03832361Phase 2Recruiting
- Start
- Jul 2020
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirvetuximab soravtansine in endometrial cancer (EC). Primary endpoint: Objective Response Rate at 5 years. Started Jul 2020; status: recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03832361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832361.